Acadia Pharmaceuticals Inc.
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 7 name spellings.
12
Ending by 2030
Nov 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 9, 2026The maintenance fee for Combination of pimavanserin and risperidone for the treatment of psychosis (US 9,050,343) comes due Dec 9, 2026. Unpaid by Jun 9, 2027, it lapses early.
- 1 fee due Mar 24, 2027The maintenance fee for Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity (US 10,421,710) comes due Mar 24, 2027. Unpaid by Sep 24, 2027, it lapses early.
- 1 fee due Apr 22, 2027The maintenance fee for Formulations of Pimavanserin (US 10,449,185) comes due Apr 22, 2027. Unpaid by Oct 22, 2027, it lapses early.
- 1 fee due May 28, 2027The maintenance fee for Crystalline Forms of Trofinetide (US 11,827,600) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.
- 3 fees due Jun 12 to 30, 2027 · next Jun 12
- 1 fee due Sep 24, 2027The maintenance fee for Methods for Preparing N-(4-Fluorobenzyl)-N-(1-Methylpiperidin-4-YL)-N'-(4-(2-Methylpropyloxy)PHENYLMETHYL)CARBAMIDE and Its Tartrate Salt and Polymorphic Form (US 10,597,363) comes due Sep 24, 2027. Unpaid by Mar 24, 2028, it lapses early.
- 1 fee due Nov 12, 2027The maintenance fee for Formulations of Pimavanserin (US 10,646,480) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,456,317 | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity In force · From the USPTO record | In force | From the USPTO record | |
| US 9,458,082 | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity In force · From the USPTO record | In force | From the USPTO record | |
| US 7,790,899 | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms In force · From the USPTO record | In force | From the USPTO record | |
| US 7,732,462 | Selective Serotonin 2A/2C Receptor Inverse Agonists as Therapeutics for Neurodegenerative Diseases In force · High confidence | In force | High confidence | |
| US 9,422,225 | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity In force · From the USPTO record | In force | From the USPTO record | |
| US 7,868,176 | Salts of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-y1)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and their preparation In force · From the USPTO record | In force | From the USPTO record | |
| US 10,421,710 | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity In force · From the USPTO record | In force | From the USPTO record | |
| US 7,863,296 | Selective serotonin receptor inverse agonists as therapeutics for disease In force · From the USPTO record | In force | From the USPTO record | |
| US 7,732,615 | N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms In force · From the USPTO record | In force | From the USPTO record | |
| US 7,820,695 | Selective serotonin receptor inverse agonists as therapeutics for disease In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 47: 2 patents in force now held by others · 38 lapsed for an unpaid fee · 26 ended at full term · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 pending · 4 abandoned · 31 no status recorded